Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives
Immunotherapy Advances · 01.01.2024 · 4 (1)
DOI: 10.1093/immadv/ltae009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 07.11.2024. Verfasst von Hanna IJspeert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jeffrey Modell Foundation, Pharming Technologies.
Abstract (Originalsprache)
The phosphoinositide-3-kinase (PI3K) pathway function is crucial to the normal development, differentiation, and function of immune cells including B, T, and NK cells. Following the description of two cohorts of patients with an inboirn error of immunity (also known as primary immunodeficiency) with gain-of-function variants in the PIK3CD gene a decade ago, the disease entity activated PI3K delta syndrome (APDS) was named. Since then, many more patients with PIK3CD variants have been described, and loss-of-function variants in PIK3R1 and PTEN have also been linked to APDS. Importantly, the availability of small molecules that inhibit the PI3K pathway has enabled targeted treatment of APDS patients. In this review, we define (i) the PI3K pathway and its role in inborn errors of immunity; (ii) the clinical and immunological presentation of APDS1 (PIK3CD GOF), APDS2 (PIK3R1 LOF), and related disorders; (iii) Diagnostic approaches to identify and functionally validate the genetic causes of disease; (iv) therapeutic interventions to target PI3K hyperactivation; and finally (v) current challenges and future perspectives that require attention for the optimal treatment of patients with APDS and APDS-L diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- Academic Center for Rare Immunological Diseases (RIDC), Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- Division of Allergy & Clinical Immunology, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
- The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Melbourne, VIC, Australia.
- Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Alfred Hospital, Melbourne, VIC, Australia.
ORCID-Profile: Hanna IJspeert, Virgil A S H Dalm, Menno C van Zelm, Emily S J Edwards
Förderung
- Jeffrey Modell Foundation
- Pharming Technologies
Zitieren
APA
IJspeert, H., Dalm, V. A. S. H., van Zelm, M. C., & Edwards, E. S. J. (2024). Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives. Immunotherapy Advances, 4(1). https://doi.org/10.1093/immadv/ltae009
Vancouver
IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ. Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives. Immunotherapy Advances. 2024;4(1). doi:10.1093/immadv/ltae009
BibTeX
@article{IJspeert2024,
author = {IJspeert, Hanna and Dalm, Virgil A S H and van Zelm, Menno C and Edwards, Emily S J},
title = {Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives},
journal = {Immunotherapy Advances},
year = {2024},
volume = {4},
number = {1},
doi = {10.1093/immadv/ltae009}
}
EUVIMED